Prescription medicine

Motixafortide Brand names: Aphexda

Motixafortide (Aphexda) is a prescription medicine with an FDA approval on record since 2023. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the motixafortide FDA label on DailyMed (effective June 4, 2026, Gamida Cell Inc.); the NDA 217159 record on Drugs@FDA; every motixafortide label on DailyMed.

Highlights of the record

FDA label of June 4, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Forms and strengths

62 mg/1.7ml

Injection (powder) (lyophilized) for solution.

On the market

Earliest approval on file: September 8, 2023 Aphexda, Ayrmid Pharma; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 2 of which 0 under generic applications, 2 under brand applications, repackagers included
Last listed patent: December 29, 2041 Aphexda injection; not a generic launch date

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 99 through July 30, 2026

What is motixafortide used for?

From the label: indications and usage
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Source: FDA drug label (APHEXDA), NDA217159 (Ayrmid Pharma), as published by Gamida Cell Inc., effective June 4, 2026 (SPL set e704b2db-f119-40ba-9346-9229e3281c9e), via openFDA; the full label on DailyMed

Is there a generic for motixafortide (Aphexda)?

No generic motixafortide is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 2 patents for Aphexda injection, the last expiring on December 29, 2041. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

2023 earliest approval on file
2041 last listed patent

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What does the motixafortide label say about other medicines?

The motixafortide label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Medicine named	Section	What the label says
Acetaminophen	warnings and precautions	The addition of analgesic premedication (e.g., acetaminophen) is recommended. ( 5.2 ) Tumor Cell Mobilization in Patients with Leukemia:
Filgrastim	warnings and precautions	Tumor cells may be released from marrow during HSC mobilization with APHEXDA and filgrastim.

Check motixafortide against other medicines

What do FAERS reports show for motixafortide?

The FDA Adverse Event Reporting System holds 99 reports that list motixafortide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 5 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

Injection Site Pain (named in the label)37
Pruritus (named in the label)25
Urticaria (named in the label)20
Flushing (named in the label)16
Rash (named in the label)12
Injection Site Erythema (named in the label)10
Paraesthesia (named in the label)10
Injection Site Reaction (named in the label)9

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Motixafortide side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other